Thursday, March 23, 2023 | Back issues
Courthouse News Service Courthouse News Service

Drug Antitrust

MINNEAPOLIS - Boehringer Ingelheim conspired with Barr Pharmaceuticals et al. to delay introduction of a generic form of the stroke drug Aggrenox, costing consumers millions of dollars, a union health care fund claims in a federal antitrust class action.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.